Allogene Therapeutics (ALLO) Stock Forecast & Price Target

→ Could Bitcoin Literally FORCE This Crypto To Rocket Up? (From Paradigm Press) (Ad)

$3.48

-0.03 (-0.85%)

(As of 09:40 AM ET)

Allogene Therapeutics Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Moderate Buy
Based on 7 Analyst Ratings

Analysts' Consensus Price Target

$12.94
271.77% Upside

High Forecast	$28.00
Average Forecast	$12.94
Low Forecast	$7.00

Type	Current Forecast 4/19/23 to 4/18/24	1 Month Ago 3/20/23 to 3/19/24	3 Months Ago 1/19/23 to 1/19/24	1 Year Ago 4/19/22 to 4/19/23
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	5 Buy rating(s)	7 Buy rating(s)	8 Buy rating(s)	9 Buy rating(s)
Hold	2 Hold rating(s)	3 Hold rating(s)	3 Hold rating(s)	3 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$12.94	$12.45	$15.29	$17.23
Predicted Upside	271.77% Upside	163.71% Upside	211.25% Upside	161.65% Upside

Get Allogene Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for ALLO and its competitors with MarketBeat's FREE daily newsletter.

Ad Birch Gold

IRS Loophole Gives Americans An Escape From Inflation

In the years immediately following 2008-09, as the economy stagnated, gold exploded in value. Today, Goldman Sachs is telling its clients that gold may reach $2,250 within the next few years. Don't miss your chance to diversify your savings.

Request your info kit on gold now

ALLO Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ALLO Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Allogene Therapeutics Stock vs. The Competition

Type	Allogene Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	2.75	2.68	2.49
Consensus Rating	Moderate Buy	Moderate Buy	Hold
Predicted Upside	275.12% Upside	934.64% Upside	12.25% Upside
News Sentiment Rating	Positive News	Neutral News	Positive News

Recent Analyst Ratings and Stock Forecasts

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Action	Rating	Price Target	Upside/Downside on Report Date
3/19/2024	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00	+138.38%
3/15/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$10.00	+130.41%
2/27/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Overweight ➝ Overweight	$9.00 ➝ $8.00	+54.44%
1/5/2024	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
1/5/2024	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform
12/8/2023	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$7.00	+177.78%
8/3/2023	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$28.00	+497.01%
7/12/2023	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target		$20.00 ➝ $18.00	+209.28%
5/4/2023	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target		$8.00 ➝ $7.50	+31.12%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 10:00 AM ET.

ALLO Price Target - Frequently Asked Questions

What is Allogene Therapeutics's consensus rating and price target?: According to the issued ratings of 7 analysts in the last year, the consensus rating for Allogene Therapeutics stock is Moderate Buy based on the current 2 hold ratings and 5 buy ratings for ALLO. The average twelve-month price prediction for Allogene Therapeutics is $12.94 with a high price target of $28.00 and a low price target of $7.00. Learn more on ALLO's analyst rating history.
Do Wall Street analysts like Allogene Therapeutics more than its competitors?: Analysts like Allogene Therapeutics more than other Medical companies. The consensus rating score for Allogene Therapeutics is 2.71 while the average consensus rating score for medical companies is 2.68. Learn more on how ALLO compares to other companies.
Does Allogene Therapeutics's stock price have much upside?: According to analysts, Allogene Therapeutics's stock has a predicted upside of 181.06% based on their 12-month stock forecasts.

What analysts cover Allogene Therapeutics?: Allogene Therapeutics has been rated by HC Wainwright, JPMorgan Chase & Co., and Royal Bank of Canada in the past 90 days.

Stock Ratings Reports and Tools

Related Companies:

Today's Ratings:

Top Rated Stocks:

More Ratings Tools:

This page (NASDAQ:ALLO) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Allogene Therapeutics (ALLO) Stock Forecast & Price Target

Allogene Therapeutics Consensus Analyst Rating and Stock Price Forecast (2024)

Analysts' Consensus Rating

Analysts' Consensus Price Target

ALLO Analyst Ratings By Month

ALLO Price Targets by Month

Allogene Therapeutics Stock vs. The Competition

Recent Analyst Ratings and Stock Forecasts

ALLO Price Target - Frequently Asked Questions

Stock Ratings Reports and Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info